ABSTRACT
In Sweden, the key organization involved in the pricing and reimbursement process for drugs is the Dental and Pharmaceutical Benefits Agency (Tandvårds-och läkemedelsförmånsverket [TLV]), formerly known as the Pharmaceutical Benefits Board (Läkemedelsförmånsnämnden [LFN]). The TLV is a central government agency that determines whether a pharmaceutical product or dental care procedure shall be subsidized by the state and has decisive power at a national level.1 It makes a simultaneous decision on the drug’s pricing and reimbursement.
